hrcak mascot   Srce   HID

Pregledni rad

Occurrence of Hepatocellular Carcinoma in Patients with Chronic hepatitis C Treated with Direct-Acting Antiviral Therapy

Lucija Kuna
Martina Smolić
Tomislav Kizivat
Robert Smolić

Puni tekst: engleski, pdf (123 KB) str. 81-81 preuzimanja: 30* citiraj
APA 6th Edition
Kuna, L., Smolić, M., Kizivat, T. i Smolić, R. (2020). Occurrence of Hepatocellular Carcinoma in Patients with Chronic hepatitis C Treated with Direct-Acting Antiviral Therapy. Medicus, 29 (1 Hepatologija danas), 81-81. Preuzeto s https://hrcak.srce.hr/232204
MLA 8th Edition
Kuna, Lucija, et al. "Occurrence of Hepatocellular Carcinoma in Patients with Chronic hepatitis C Treated with Direct-Acting Antiviral Therapy." Medicus, vol. 29, br. 1 Hepatologija danas, 2020, str. 81-81. https://hrcak.srce.hr/232204. Citirano 22.10.2020.
Chicago 17th Edition
Kuna, Lucija, Martina Smolić, Tomislav Kizivat i Robert Smolić. "Occurrence of Hepatocellular Carcinoma in Patients with Chronic hepatitis C Treated with Direct-Acting Antiviral Therapy." Medicus 29, br. 1 Hepatologija danas (2020): 81-81. https://hrcak.srce.hr/232204
Harvard
Kuna, L., et al. (2020). 'Occurrence of Hepatocellular Carcinoma in Patients with Chronic hepatitis C Treated with Direct-Acting Antiviral Therapy', Medicus, 29(1 Hepatologija danas), str. 81-81. Preuzeto s: https://hrcak.srce.hr/232204 (Datum pristupa: 22.10.2020.)
Vancouver
Kuna L, Smolić M, Kizivat T, Smolić R. Occurrence of Hepatocellular Carcinoma in Patients with Chronic hepatitis C Treated with Direct-Acting Antiviral Therapy. Medicus [Internet]. 2020 [pristupljeno 22.10.2020.];29(1 Hepatologija danas):81-81. Dostupno na: https://hrcak.srce.hr/232204
IEEE
L. Kuna, M. Smolić, T. Kizivat i R. Smolić, "Occurrence of Hepatocellular Carcinoma in Patients with Chronic hepatitis C Treated with Direct-Acting Antiviral Therapy", Medicus, vol.29, br. 1 Hepatologija danas, str. 81-81, 2020. [Online]. Dostupno na: https://hrcak.srce.hr/232204. [Citirano: 22.10.2020.]
Puni tekst: hrvatski, pdf (123 KB) str. 81-88 preuzimanja: 86* citiraj
APA 6th Edition
Kuna, L., Smolić, M., Kizivat, T. i Smolić, R. (2020). Pojava hepatocelularnog karcinoma u pacijenata oboljelih od kroničnog hepatitisa C liječenih direktnodjelujućim antivirusnim lijekovima. Medicus, 29 (1 Hepatologija danas), 81-88. Preuzeto s https://hrcak.srce.hr/232204
MLA 8th Edition
Kuna, Lucija, et al. "Pojava hepatocelularnog karcinoma u pacijenata oboljelih od kroničnog hepatitisa C liječenih direktnodjelujućim antivirusnim lijekovima." Medicus, vol. 29, br. 1 Hepatologija danas, 2020, str. 81-88. https://hrcak.srce.hr/232204. Citirano 22.10.2020.
Chicago 17th Edition
Kuna, Lucija, Martina Smolić, Tomislav Kizivat i Robert Smolić. "Pojava hepatocelularnog karcinoma u pacijenata oboljelih od kroničnog hepatitisa C liječenih direktnodjelujućim antivirusnim lijekovima." Medicus 29, br. 1 Hepatologija danas (2020): 81-88. https://hrcak.srce.hr/232204
Harvard
Kuna, L., et al. (2020). 'Pojava hepatocelularnog karcinoma u pacijenata oboljelih od kroničnog hepatitisa C liječenih direktnodjelujućim antivirusnim lijekovima', Medicus, 29(1 Hepatologija danas), str. 81-88. Preuzeto s: https://hrcak.srce.hr/232204 (Datum pristupa: 22.10.2020.)
Vancouver
Kuna L, Smolić M, Kizivat T, Smolić R. Pojava hepatocelularnog karcinoma u pacijenata oboljelih od kroničnog hepatitisa C liječenih direktnodjelujućim antivirusnim lijekovima. Medicus [Internet]. 2020 [pristupljeno 22.10.2020.];29(1 Hepatologija danas):81-88. Dostupno na: https://hrcak.srce.hr/232204
IEEE
L. Kuna, M. Smolić, T. Kizivat i R. Smolić, "Pojava hepatocelularnog karcinoma u pacijenata oboljelih od kroničnog hepatitisa C liječenih direktnodjelujućim antivirusnim lijekovima", Medicus, vol.29, br. 1 Hepatologija danas, str. 81-88, 2020. [Online]. Dostupno na: https://hrcak.srce.hr/232204. [Citirano: 22.10.2020.]

Sažetak
Patients with chronic liver disease are known to be more likely to develop hepatocellular carcinoma (HCC). Although direct-acting antivirals have proven successful in eliminating the hepatitis C virus RNA from blood circulation, the HCV RNA can still remain present in liver tissue or peripheral blood mononuclear cells – a condition known as occult HCV infection. There have been numerous concerns related to the recurrence of HCC after DAA treatment of hepatocytes infected with chronic HCV. One of the major risk factors leading to de novo HCC is the chronicity of HCV in liver cells. Moreover, numerous studies investigated the change of HCV-infected hepatocytes into HCC. However, the molecular mechanisms leading to the progression of chronic HCV infection into HCC, as well as the effect of HCV on the alteration of DNA ploidy that leads to recurrence of HCC after DAA treatment, are still unclear. Therefore, this article examines the risk factors that could lead to the development of HCC after treatment of HCV with DAAs, such as the role of liver cirrhosis, reactivation of hepatitis B virus, alteration of DNA ploidy and occult HCV infection.

Ključne riječi
hepatitis C virus; hepatocellular carcinoma; direct-acting antiviral therapy

Hrčak ID: 232204

URI
https://hrcak.srce.hr/232204

[hrvatski]

Posjeta: 192 *